Trial reportJournal of neuro-oncology2020
Surgical treatment and survival outcome of patients with adult thalamic glioma: a single institution experience of 8 years.
Trial report in Journal of neuro-oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes.Journal of neuro-oncology · 2021Pooled it
- [Development and Evaluation of Prognostic Nomogram Model for Adult Ventricle Glioma Patients].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2022Trial
- The clinical and molecular landscape of thalamic glioma.Neuro-oncology · 2026Article
- Strategy of adult thalamic glioma surgery: Thoughts and practices based on thalamic glioma classification.Neurosurgical review · 2026Article
- Intraoperative electrocorticography-guided glioma surgery: impact on extent of resection and functional preservation.Frontiers in oncology · 2026Article
- Clinical Nomogram Model for Predicting the Prognosis of Patients with Brainstem Glioma : A Population-Based Study.Journal of Korean Neurosurgical Society · 2025Article
- Clinical and survival differences between thalamic glioblastoma and thalamic diffuse midline glioma, H3 K27-altered.Journal of neuro-oncology · 2025Article
- Integrated clinicopathological-radiomic-blood model for glioma survival prediction via machine learning: a multicenter cohort study.Neurosurgical review · 2025Article
- The impact of maximized resection and standardized systemic therapy on overall survival in adult patients with thalamic gliomas.Frontiers in oncology · 2025Article
- High-Grade Thalamic Glioma: Case Report with Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Long-Term Outcomes and Survival Rates of Patients Undergoing Biopsy Vs. Maximum Safe Resection for Thalamic Lesions: A Short Review on Current Evidence.Galen medical journal · 2024Review
- Prognostic nomogram models for predicting survival probability in elderly glioblastoma patients.Journal of cancer research and clinical oncology · 2023Article
- Artificial Intelligence Algorithm-Based Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) in the Treatment of Glioma Biopsy.Contrast media & molecular imaging · 2022Article
- Molecular Characteristics of Thalamic Gliomas in Adults.Journal of molecular neuroscience : MN · 2021Article
- The Korean Society for Neuro-Oncology (KSNO) Guideline for Adult Diffuse Midline Glioma: Version 2021.1.Brain tumor research and treatment · 2021Article
- A prognostic nomogram for patients with newly diagnosed adult thalamic glioma in a surgical cohort.Neuro-oncology · 2021Article
- H3K27M andNeuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
purposeGiven the rarity in the population with adult thalamic gliomas (ATGs), comprehensive characteristics, treatments and survival outcome are not well characterized. This study was conducted to investigate the comprehensive characteristic and treatment of ATGs and identify the prognostic factors associated with overall survival (OS).
methodsA retrospective analysis of newly diagnosed ATGs who underwent surgical resection consecutively was conducted. Survival analysis of OS was performed by Kaplan-Meier analysis. Cox proportional hazard model was used to investigate the possible prognostic factors associated with OS.
resultsA total of 102 patients with ATG were enrolled in this study. The median age was 41 years (range 18-68 years). There were 56 (54.9%) males. Sixty-two patients (60.8%) had glioblastoma (GBM). Among these patients, 46 patients (45.1%) had GTR/NTR, 50 patients (49.0%) had STR and 6 patients (5.9%) had PR. Postoperatively, 71.6% of these patients received adjuvant therapy. The median OS was 13.6 months (range 1 week-75 months). COX regression analysis revealed that ATG patients with longer duration of symptoms (p = 0.024), better pre-KPS (p = 0.045), maximal resection (p = 0.013), or lower tumor grade (p = 0.002) had longer OS, and these predictors are considered as independent prognostic factors. Survival analysis showed that ATGs with GTR/NTR plus chemoradiotherapy had significant OS advantage compared with other treatment regimens.
conclusionsThis study comprehensively summarized the characteristics, treatments and survival outcomes of ATGs in the largest sample size. Maximal surgical resection can bring survival benefit. Combined-modality therapy regimen of GTR/NTR plus chemoradiotherapy may be better beneficial for OS than other regimens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.